CD8A and melanoma: This immunomodulatory effect of crizotinib was further validated in the YUMM1.7 melanoma model, where combination treatment similarly reduced M2 macrophage populations and enhanced IFN‐γ+ CD8+ T‐cell responses (Figure S2).